Get the Stockscreener App
4.64
9.18%
0.39
Pre-market:
4.57
-0.07
-1.51%
Phathom Pharmaceuticals Inc stock is traded at $4.64, with a volume of 800.22K.
It is up +9.18% in the last 24 hours and up +68.12% over the past month.
Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small-molecule potassium competitive acid blocker medicine that blocks acid secretion in the stomach. Vonoprazan shows rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of Helicobacter pylori infection.
See More
Previous Close:
$4.25
Open:
$4.28
24h Volume:
800.22K
Relative Volume:
0.50
Market Cap:
$323.92M
Revenue:
-
Net Income/Loss:
$-297.11M
P/E Ratio:
-0.894
EPS:
-5.19
Net Cash Flow:
$-216.95M
1W Performance:
+15.42%
1M Performance:
+68.12%
6M Performance:
-46.73%
1Y Performance:
-50.74%
1-Day Range:
$4.25
$4.69
1-Week Range:
$3.92
$4.69
52-Week Range:
$2.21
$19.71
Phathom Pharmaceuticals Inc Stock (PHAT) Company Profile
Name
Phathom Pharmaceuticals Inc
Sector
Industry
Phone
(877) 742-8466
Address
100 CAMPUS DRIVE,, FLORHAM PARK, NJ
Compare PHAT with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PHAT
Phathom Pharmaceuticals Inc
|
4.64 | 287.63M | 0 | -297.11M | -216.95M | -5.19 |
|
ONC
Beone Medicines Ltd Adr
|
245.93 | 25.76B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
445.43 | 114.53B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.415 | 40.54M | 0 | 0 | 0 | 0.00 |
|
VRNA
Verona Pharma Plc Adr
|
84.10 | 6.44B | 0 | -153.72M | -103.81M | -2.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
490.81 | 65.13B | 14.09B | 4.50B | 2.96B | 39.28 |
Phathom Pharmaceuticals Inc Stock (PHAT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-14-25 | Initiated | Cantor Fitzgerald | Overweight |
| May-03-24 | Initiated | Stifel | Buy |
| Jan-05-24 | Reiterated | Needham | Buy |
| Aug-09-23 | Initiated | H.C. Wainwright | Buy |
| May-11-23 | Upgrade | Evercore ISI | In-line → Outperform |
| Mar-13-23 | Initiated | Craig Hallum | Buy |
| Oct-21-22 | Initiated | Jefferies | Buy |
| May-06-22 | Downgrade | Evercore ISI | Outperform → In-line |
| May-12-21 | Upgrade | Goldman | Sell → Neutral |
| Feb-17-21 | Initiated | BMO Capital Markets | Outperform |
| Feb-02-21 | Initiated | Guggenheim | Buy |
| Jun-26-20 | Downgrade | Goldman | Neutral → Sell |
| Nov-20-19 | Initiated | Evercore ISI | Outperform |
| Nov-19-19 | Initiated | Goldman | Neutral |
| Nov-19-19 | Initiated | Jefferies | Buy |
| Nov-19-19 | Initiated | Needham | Buy |
View All
Phathom Pharmaceuticals Inc Stock (PHAT) Latest News
ProShare Advisors LLC Has $116,000 Stock Position in Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) - Defense World
Investors Still Aren't Entirely Convinced By Phathom Pharmaceuticals, Inc.'s (NASDAQ:PHAT) Revenues Despite 54% Price Jump - simplywall.st
MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. Raises Stake in Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) - Defense World
Deutsche Bank AG Increases Stock Holdings in Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) - Defense World
Brokerages Set Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) PT at $17.60 - Defense World
BNP Paribas Financial Markets Purchases Shares of 39,532 Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) - Defense World
Northern Trust Corp Has $3.23 Million Position in Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) - Defense World
Even after rising 39% this past week, Phathom Pharmaceuticals (NASDAQ:PHAT) shareholders are still down 89% over the past five years - simplywall.st
Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences - GlobeNewswire
GI Disease Leader Phathom to Present at 3 Elite Healthcare Conferences: Goldman Sachs, Jefferies, H.C. Wainwright - Stock Titan
(PHAT) Proactive Strategies - news.stocktradersdaily.com
Phathom pharmaceuticals outlines VOQUEZNA expansion targets and cost-saving measures for profitability by 2026 - MSN
After Plunging -45.82% in 4 Weeks, Here's Why the Trend Might Reverse for Phathom Pharmaceuticals (PHAT) - MSN
Phathom Pharmaceuticals Sees Unusually High Options Volume (NASDAQ:PHAT) - Defense World
Phathom Pharmaceuticals surges 50% following large insider purchase - MSN
Phathom Pharmaceuticals (PHAT) Shares Surge After Board Member's Large Purchase - GuruFocus
Insider Buying: Asit Parikh Acquires Additional Shares of Phatho - GuruFocus
Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) Shares Acquired by Barclays PLC - Defense World
Finance Watch: Unity Lays Off All Employees As It Evaluates Alternatives - insights.citeline.com
HC Wainwright Cuts Phathom Pharmaceuticals (NASDAQ:PHAT) Price Target to $20.00 - Defense World
Retail Interest in Phathom Soars As Firm Pledges Profit Path, Cuts Costs After Q1 Miss - MSN
Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) Just Reported, And Analysts Assigned A US$18.63 Price Target - Yahoo Finance
The Goldman Sachs Group Issues Pessimistic Forecast for Phathom Pharmaceuticals (NASDAQ:PHAT) Stock Price - Defense World
Phathom Pharmaceuticals First Quarter 2025 Earnings: Misses Expectations - Yahoo
H.C. Wainwright cuts Phathom Pharma stock target to $20, keeps Buy rating - Investing.com Canada
Phathom Pharmaceuticals (PHAT) Price Target Lowered by Goldman S - GuruFocus
Phathom Pharmaceuticals (PHAT) Target Price Lowered by Guggenhei - GuruFocus
Phathom Pharmaceuticals (PHAT) Maintains Buy Rating as Price Tar - GuruFocus
Phathom Pharmaceuticals (PHAT) Maintains Buy Rating as Price Target Drops | PHAT Stock News - GuruFocus
Phathom Pharmaceuticals (PHAT) Price Target Reduced by Guggenhei - GuruFocus
Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) Q1 2025 Earnings Call Transcript - Insider Monkey
Phathom Pharmaceuticals (PHAT) Price Target Reduced by Guggenheim | PHAT Stock News - GuruFocus
PHAT Faces Price Target Cut Amidst Restructuring Efforts | PHAT Stock News - GuruFocus
Phathom Pharmaceuticals Inc (PHAT) Q1 2025 Earnings Call Highlights: Strong Revenue Growth Amid ... - Yahoo Finance
Phathom Pharmaceuticals Inc (PHAT) Q1 2025 Earnings Call Highlig - GuruFocus
Phathom Pharmaceuticals Reports Q1 2025 Financial Results - TipRanks
Phathom Pharmaceuticals Eyes Profitability Amid Growth - TipRanks
Phathom Pharmaceuticals Q1 2025 Earnings Call Transcript - MarketBeat
Phathom Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | PHAT Stock News - GuruFocus
Phathom Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Phathom Pharmaceuticals Grants 186,508 Shares Package to New Sales Chief in Strategic Hire - Stock Titan
Phathom (PHAT) Implements Strategic Shift for Long-Term Growth | - GuruFocus
Phathom Pharmaceuticals Q1 2025 Earnings: EPS Matches Estimates at -$1.18, Revenue Falls Short at $28.5 Million - GuruFocus
Arvinas ends plans for two Phase 3 breast cancer trials; Phathom makes cuts - Endpoints News
Phathom Pharmaceuticals stock hits 52-week low at $3.8 By Investing.com - Investing.com India
Phathom Pharmaceuticals to Report First Quarter 2025 Financial R - GuruFocus
Phathom Pharmaceuticals stock hits 52-week low at $3.8 - Investing.com
Earnings call transcript: Phathom Pharmaceuticals beats Q1 2025 earnings expectations - Investing.com
Phathom Pharmaceuticals, Inc. (PHAT) Reports Q1 Loss, Tops Revenue Estimates - Yahoo Finance
Phathom Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update - The Manila Times
Phathom Pharmaceuticals Reports First Quarter 2025 Financial Res - GuruFocus
Phathom Pharmaceuticals Inc Stock (PHAT) Financials Data
Revenue
Net Income
Cash Flow
EPS
6.48%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):